MetaCap

GRAIL (GRAL) vs RadNet (RDNT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

GRAIL (GRAL) has outperformed RadNet (RDNT) over the past year, gaining 6.1% versus a loss of 16.0%. RadNet is the larger company by market cap ($5.49 billion vs $4.46 billion), about 1.2 times the size, while GRAIL is growing revenue faster (+17.2% vs +11.5%). RadNet converts more of its revenue into profit, with a net margin of -0.9% versus -277.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRAL+6.09%RDNT-16.01%
+76%+8%-60%
Nov 21, 20251 yearNov 20, 2026
GRAL+578.86%RDNT+19.22%
+926%+430%-65%
Jun 10, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRAL versus RDNT key metrics
MetricGRALRDNT
Share price$99.25$69.71
Market cap$4.46B$5.49B
1-day change-5.33%+0.29%
YTD return+15.96%-2.30%
1-year return+6.09%-16.01%
5-year return—+159.63%
Forward P/E—66.39
EPS (TTM)$-9.22$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$147.17M$2.04B
Revenue growth (YoY)+17.18%+11.51%
Net income (latest FY)$-408.35M$-18.65M
Operating margin-381.98%3.04%
Net margin-277.47%-0.91%
52-week high$166.48$85.84
52-week low$41.50$50.82
Distance from 52-week high-40.38%-18.79%
Analyst consensusbuystrong_buy
Avg. price target upside+40.49%+39.15%
Average volume1.03M688.04K
Shares outstanding44.96M78.77M
Employees91012,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRAL has outperformed RDNT by 22.1 percentage points over the past year.
  • RadNet is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -277.5 cents for GRAIL.
  • GRAIL grew revenue faster in its latest fiscal year (+17.18% vs +11.51%).

About GRAIL

GRAL stock →

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.

Health Care · Medical Specialities · 910 employees

About RadNet

RDNT stock →

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health.

Health Care · Medical Specialities · 12,000 employees

GRAL vs RDNT FAQ

Which is bigger, GRAIL or RadNet?

RadNet (RDNT) is larger, with a market capitalization of $5.49B compared with $4.46B for GRAIL (GRAL).

Which stock has performed better over the past year, GRAL or RDNT?

GRAL returned +6.09% over the past 12 months, compared with -16.01% for RDNT (price return, excluding dividends). Past performance does not predict future results.

Are GRAIL and RadNet in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons